EBV-specific TCR-T cell with anti-PD1 auto-secreted element

N/A

Report date: 2024/10/24 20:00:07

Base Information

Drug NameEBV-specific TCR-T cell with anti-PD1 auto-secreted element
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionProgrammed cell death protein 1 modulatorsT lymphocyte replacements
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTcrcure Biopharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTcrcure Biopharma Ltd
Inactive CompaniesN/A
Active IndicationsSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A